Successfully enlisted in Emerging Market Platform, stock code: 6875
Taipei Taiwan, Feb. 22, 2022 -- Pharmosa Biopharm Inc. (TPEx stock code: 6875, "PBI") proudly announces that the company is successfully enlisted in Emerging Market today with the listed price of NT$45 per share. The lead security underwriter is reputable Cathay Securities Corporation.
Pharmosa Biopharm Inc. (PBI) is a drug delivery company focusing on drug and device combination product by exploiting our proprietary formulation and manufacturing technology, targeting the areas of pulmonary vascular related diseases. In 2019, PBI has completed phase I clinical trial in USA for project L606, and Phase III pivotal trials is currently on the go. Due to Covid-19, the timeline for Phase III is anticipated to delay, yet PBI remains optimistic for the outcomes, considering the advantageous regulatory pathway of 505(b)(2). For project L608, PBI also has plans in the near term to submit IND packages and to initiate phase I clinical trial in Taiwan.
Disclaimer: Drug development timeline is often long and with uncertainties, many of which are beyond our control. The information contained herein does not constitute a solicitation of any securities. For corporate development and filings, please refer to Taiwan MOPs for public information disclosures.
